topicals for seniors

Topicals: The Real Gateway Drug for Senior Citizens


Topicals: The Real Gateway Drug for Senior Citizens

Cannabis topicals are having a moment. From
A-list celebrities using Lord Jones balms to soothe aching feet at the Golden
Globes to professional athletes debuting their own line of muscle rub,
transdermal products infused with cannabinoids seem to be everywhere.

But it isn’t just millennials and the Hollywood elite jumping on the bandwagon. An increasing number of senior citizens are also turning to topicals, often desperate to alleviate a painful and often debilitating condition that affects nearly 54 million American adults: arthritis.

The disease, which causes aches, swelling and stiffness in the joints and muscles, is typically treated with a combination of medications including steroids and opiates, which may have dramatic side effects. However, cannabis is becoming a popular and viable alternative. Infused creams and lotions work when the products’ cannabinoids bind to the network of cannabinoid receptors called CB2 receptors on the skin, without needing to enter the bloodstream. This means people using topicals infused with psychoactive cannabinoids such as THC will not feel a cerebral effect — only localized relief. Transdermal patches, however, do allow the cannabinoids to enter the bloodstream and travel to receptors in the brain, but because the release is so slow, it’s also unlikely to impart a high feeling.

While research on the efficacy of topicals is limited, there have been some promising results. A 2015 study published in the European Journal of Pain found that, when applied transdermally to rats with arthritic joints, the cannabinoid CBD (cannabidiol) offered relief. Another study conducted in 2017 on rats with osteoarthritis (the most common type of arthritis, wherein bone cartilage breaks down over time) concluded CBD prevents pain and nerve damage. In fact, scientists are also exploring evidence that concludes CB2 receptors themselves may be responsible for regulating inflammation — one of the main issues arthritis causes.

The science is still early, but according to Radicle Health founder and nurse Eloise Theisen, CBD topicals appear to help with inflammation and itchiness, but people should try a THC topical — or a combination of THC and CBD — if they’re not finding relief from a CBD-only product.

Since the average senior citizen in the United
States takes around five prescription medications daily, concerns about
interactions between drugs, side effects and potentials for abuse have many
seeking another way.

And since those who might be averse to getting high from smoking or eating cannabis are often not intimidated by using a non-psychoactive cannabis balm, topicals offer a way to discover the healing properties of cannabis while eliminating the fear of Grandma and Grandpa getting too buzzed.

‘Once He Went Off the Pharmaceuticals….’

Karen Rumics Averill is a 63-year-old business
owner from Oregon who began making her own cannabis-infused topicals a few
years ago to help her husband. He was suffering from a severe type of arthritis
called ankylosing spondylitis, also known as “curved back syndrome.”

“He was initially put on Enbrel, which is an
injection, and he was actually receiving twice the dose that is normally
required,” Averill said. “Then, [the doctors] put him on Oxycontin and Vicodin
and then all of a sudden one day, at two in the morning, we’re rushing him to
the emergency room for a bleeding ulcer and they had to remove him from all of
those drugs.”

She believes the drugs her husband had been
prescribed were actually making his condition worse.

“Once he went off of [pharmaceuticals], he became
more mobile, more active. He wasn’t comatose on the couch because he was
over-medicated.”

Averill began experimenting, utilizing byproducts
from top-shelf indica strains to infuse in coconut oil, creating a THC-infused topical.

“Actually, my 94-year-old aunt is now using it
for her arthritis. She called me
yesterday and said it works great!” Averill said.

Bringing Seniors to Cannabis

For many within the cannabis industry, one of the biggest challenges is getting accurate information to the general public — without being overwhelming or unconvincing. After getting phone call after phone call from seniors asking about their transdermal product, the team at NanoSphere Health Sciences decided they needed to focus not on getting their products to seniors, but on bringing the seniors to them.

“A lot of times, the way that a senior gets our
product is because a niece or nephew, granddaughter, son or daughter has gone
in, bought them the product and then told them that they need to use it, versus
them actually going into the dispensary and purchasing the product themselves,”
said Crystal Colwell, marketing director for NanoSphere.

So the company decided to partner with several dispensaries in their home state of Colorado, offering residents of nearby assisted living facilities and 55-plus communities round-trip bus rides to their locations in order to educate them on the many useful applications of cannabis. They also work with the non-profit group Realm of Caring in order to further their outreach towards the senior citizen demographic. Colwell says the feedback has been remarkable.

“We had one woman who had such severe arthritis
in her hands that she was unable to open her hands all the way,” Colwell said.
“One of her most favorite things to do is to write letters and handwritten
notes. She started using NanoSerum on her hands and she was using it once a day
for a month and after the first month she was able to open her hand and hold a
pen or a pencil in her hand again. Within a two-month time span, she was
actually able to write handwritten notes again.”

Colwell adds that while it will take time to
dismantle all the misinformation about marijuana and the ways it can be
consumed, topicals offer a non-threatening introduction to a medicine that
could make all the difference.

“A lot of misconceptions that senior citizens have is that the only time you can get relief from cannabis is if you smoke it or you ingest as an edible,” she said. “Once they learn that there are alternative applications, that’s when they become intrigued and it gets their mind going.”

Originally published in the print edition of Cannabis Now.

The post Topicals: The Real Gateway Drug for Senior Citizens appeared first on Cannabis Now.

Source link

Hemp THC beverage maker first to join major alcohol trade group

Hemp THC beverage maker first to join major alcohol trade group

Hemp THC beverage maker first to join major alcohol trade group

A Kentucky-based hemp-derived THC beverage producer is the first to join the Wine & Spirits Wholesalers of America.

CannaBuzz’s establishes a strategic connection between traditional alcohol distribution channels and the growing intoxicating hemp beverage market, according to Highly Capitalized Network.

ADVERTISEMENT

With spirits sales dropping 6% in the second quarter, according to the WSWA, hemp-derived THC beverages are proving a popular alternative.

THC-infused drink sales exceeded $1 billion nationwide in 2024, and analysts predict significant growth through 2026 as brands improve formulations and expand distribution.

But challenges remain.

Amid recognition that the 2018 Farm Bill accidentally created a hemp-derived THC market, at least 15 states have tightened restrictions on products this year, citing concerns over potency and youth access.

Cannabis advocates also express

The post Hemp THC beverage maker first to join major alcohol trade group appeared first on GrowCola.com.

Source link

Trump Posts About The Benefits Of A Cannabis Product

Trump Posts About The Benefits Of A Cannabis Product

Trump Posts About The Benefits Of A Cannabis Product

On Sunday night, President Donald Trump posted a video on Truth Social that could mark a turning point in cannabis politics. The nearly three-minute clip, produced by The Commonwealth Project, urges the federal government to cover hemp-derived CBD under Medicare, calling it “the most important senior health initiative of the century.”

The spot plays like a polished pitch. Over swelling music, the narrator declares, “You can revolutionize senior healthcare” and later, “You will deliver the most important senior health initiative of the century, cementing your legacy.” It also reminds viewers of Trump’s role in the 2018 Farm Bill, which removed hemp with up to 0.3% THC from the federal list of controlled substances and cleared the way for today’s hemp-derived cannabinoids market. The message positions CBD as both a medical breakthrough and a political milestone.

To Read The Rest Of This Article On High Times, Click Here

The post Trump Posts About The Benefits Of A Cannabis Product appeared first on Marijuana Retail Report – News and Information for Cannabis Retailers.



Source link

การเมืองที่แท้จริง : Thailand’s new PM vows to end the ‘free use’ of cannabis

MJ Biz Report – Illinois Regulators Say Curaleaf Involved In Systematic Diversion After High Level Employee Spills The Beans

MJ Biz Report – Illinois Regulators Say Curaleaf Involved In Systematic Diversion After High Level Employee Spills The Beans

I’m flabbegasted !!! MJ Biz Illinois cannabis regulators suspected “systemic diversion” at major multistate operator Curaleaf Holdings’ cultivation center in the state, a former high-level employee alleged in a recent lawsuit. According to a July 29 complaint filed in U.S. District Court in the Northern District of Illinois by Matthew Kalmick, a former Curaleaf regional compliance […]

Source link

Moonbeam Feminized Seeds

Moonbeam Feminized Seeds

Moonbeam Feminized Seeds

Description

Moonbeam Strain features compact, popcorn-sized buds that appear thick and heavy but are actually slightly fluffy to the touch. Each bud is covered with a layer of sunnily bright, sticky trichomes that impart a frosty glow. The buds are rich green with orange hairs interwoven throughout. When it comes to taste, Moonbeam has a dynamic combination of apricot, sweet citrus, and a hint of herbal spice that delivers an intriguing and revitalizing flavor. Its robust aroma is equal to its taste and fills the room with fruit, zest-like fragrance. It is also a high-yielding pest-resistant strain, which makes it a go-to among growers. The Moonbeam Feminized Seeds are available at Crop King Seeds.

Benefits and Effects

  • Brings a calming body high, great for stress after work.
  • Delivers a deeply relaxing feeling, easing you into deep rest.
  • Best enjoyed at night to help the mind fully unwind.

The post Moonbeam Feminized Seeds appeared first on Crop King Seeds.

Source link

High Tide To Open Three New Canna Cabana Locations Across Ontario And Alberta Canada

High Tide To Open Three New Canna Cabana Locations Across Ontario And Alberta Canada

High Tide To Open Three New Canna Cabana Locations Across Ontario And Alberta Canada

CALGARY, AB, Sept. 24, 2025 /PRNewswire/ – High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it will open three new Canna Cabana branded locations across Ontario and Alberta, located in North York, Etobicoke, and Fort McMurray. These openings bring High Tide’s total store count to 210 Canna Cabana branded locations across Canada, 89 in the province of Alberta and 88 in the province of Ontario.

“Momentum is clearly building across our network as we accelerate store openings in the second half of this year. Supported by our strong free cash flow profile, we continue to self-fund growth, targeting two to three new locations per month entirely from our own profits. This disciplined approach allows us to expand without relying on external capital while advancing steadily towards our stated goals,” said Raj Grover, Founder and Chief Executive Officer of High Tide.

“Just as importantly, we are focused on securing only the best real estate in markets with high growth and high revenue potential. Cities such as Fort McMurray, North York, and Etobicoke remain key to our strategy, and our multiple locations in these areas underscore our conviction in their long-term value. We expect to be announcing additional openings in the weeks and months ahead, right through to year-end,” added Mr. Grover.

NORTH YORK LOCATION

The Company’s new Canna Cabana located at 1448 Lawrence Avenue East in North York, Ontario, will begin selling recreational cannabis products and consumption accessories for adult use on September 26, 2025. Situated in a densely populated area, this location benefits from being part of a popular shopping centre. The storefront is also located at the major intersection of Lawrence Avenue and Victoria Avenue, offering excellent visibility and accessibility to local residents and commuters.

ETOBICOKE LOCATION

The Company’s new Canna Cabana located at 1020 Islington Avenue in Etobicoke, Ontario will begin selling recreational cannabis products and consumption accessories for adult use on September 27, 2025. Positioned along the busy north-south traffic artery of Islington Avenue, this new location will enjoy significant exposure to daily traffic. The location is uniquely positioned to serve both the large residential neighbourhoods nearby and the adjacent industrial and business park area, providing access to a strong daytime workforce as well as the immediate residential community.

FORT McMURRAY LOCATION

The Company’s new Canna Cabana located at 10024 Franklin Ave in Fort McMurray, Alberta, will begin selling recreational cannabis products and consumption accessories for adult use on September 29, 2025. Sitting on the southeast end of Fort McMurray as part of the downtown core provides convenient access for both local residents and visitors. The demographics of the area are an excellent fit for Canna Cabana, with a strong base of year-round workers and seasonal employees, complementing the success of the existing Canna Cabana store at the north end of town. This new location also enhances accessibility to Fort McMurray’s visitor population, given its proximity to numerous hotels and attractions.

ABOUT HIGH TIDE

High Tide, Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world’s most powerful plant. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide (HITI) is uniquely-built around the cannabis consumer, with wholly-diversified and fully-integrated operations across all components of cannabis, including:

Retail: Canna Cabana™ is the largest cannabis retail chain in Canada, with 210 current locations across British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, holding a growing 12% share of the market. In 2021, Canna Cabana became the first cannabis discount club retailer in the world. The Company also owns and operates multiple global e-commerce platforms offering accessories and hemp-derived CBD products.

Medical Cannabis Distribution: Remexian Pharma GmbH is a leading German pharmaceutical company built for the purpose of importation and wholesale of medical cannabis products at affordable prices. Among all German medical cannabis procurers, Remexian has one of the most diverse reaches across the globe and is licensed to import from 19 countries including Canada.

High Tide consistently moves ahead of the currents, having been named one of Canada’s Top Growing Companies by the Globe and Mail’s Report on Business in 2024 for the fourth consecutive year and was recognized as a top 50 company by the TSX Venture Exchange in 2022, 2024 and 2025. High Tide was also ranked number one in the retail category on the Financial Times list of Americas’ Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don’t miss the High Tide profile pages on SEDAR+ and EDGAR.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION

Media Inquiries
Carter Brownlee
Communications and Public Affairs Advisor
High Tide Inc.
cbrownlee@hightideinc.com
403-770-3080

Investor Inquiries
Vahan Ajamian
Capital Markets Advisor
High Tide Inc.
vahan@hightideinc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking information” and “forward-looking statements within the meaning of applicable securities legislation. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking statements herein include, but are not limited to, statements regarding: the timing of our new locations beginning to sell recreational cannabis products and consumption accessories for adult use, the expected benefits of the store locations, the level of competition in the area, the ability to expand at the rate of 2-3 locations per month without relying on external capital, and the announcement of further locations in the coming weeks and months. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including but not limited to the risk factors discussed under the heading “Non-Exhaustive List of Risk Factors” in Schedule A to our current annual information form, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca and www.sec.gov, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE High Tide Inc.

The post High Tide To Open Three New Canna Cabana Locations Across Ontario And Alberta Canada appeared first on Marijuana Retail Report – News and Information for Cannabis Retailers.

Source link

Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up

Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up

Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up

This opinion piece was written by Calvin Rasode, Vice President, Marketing, Brains Bioceutical

When Donald Trump tweets, the world pays attention. Sometimes it is spectacle, sometimes it is strategy, but either way, the ripple effect is real.

On September 28, 2025, he posted a video on Truth Social about cannabinoids, framing them as a game-changer for health.

It was not a policy paper or a clinical trial announcement, but it did something arguably more powerful. It injected cannabinoids into the mainstream political conversation at a time when science is finally ready to deliver.

For decades, cannabinoids have carried baggage. To some, they are shorthand for counterculture, legalisation debates, and consumer wellness fads. To others, they represent a new class of therapeutic compounds capable of reshaping medicine. Both views contain a grain of truth, but the part that matters most is the science quietly advancing behind the headlines.

In laboratories and clinics across the world, cannabinoids are no longer being tested as lifestyle products. They are being studied as pharmaceutical ingredients held to the same standards as chemotherapy agents or antivirals.

In my own experience at Brains Bioceutical, I have seen how far this shift has gone. We are not talking about casual oils or gummies. We are talking about active pharmaceutical ingredients produced under ICH-Q7 standards, backed by drug master files, and used in clinical trials approved by regulators in the United States and Europe.

The progress is real. Cannabidiol (CBD) has already been approved in the U.S. and Europe for certain rare forms of childhood epilepsy. Clinical programs are expanding into multiple sclerosis, schizophrenia, and neurodegenerative diseases. Preclinical research is pointing to potential roles in sleep disorders, pain management, and even conditions like autism. Each of these steps is slow, methodical, and expensive — but they mark the difference between hype and medicine.

That is why Trump’s September 28th video matters. Political attention can create momentum. It can pull cannabinoids out of regulatory limbo and force agencies, insurers, and policymakers to take them seriously.

This is not about celebrity endorsements or election theatrics. It is about creating the kind of environment where credible science can cross the finish line and reach patients who need new options.

The last cannabis boom was fueled by marketing promises and retail branding. The next one will be driven by data. Pharmaceutical cannabinoids are being produced with batch-to-batch consistency, tested for stability, and scrutinised by regulators. The companies working in this space are not chasing quick sales. They are building the foundation for drugs that could one day be prescribed as confidently as blood pressure pills.

Of course, the road ahead is not guaranteed. Cannabinoid research has to navigate complex regulations, shifting political winds, and the high cost of drug development. But the momentum is undeniable. With major pharmaceutical partners stepping in, with academic researchers publishing peer-reviewed studies, and with clinical data building year by year, cannabinoids are shedding their old reputation.

What Trump may have inadvertently done is give this progress a spotlight. By amplifying cannabinoids to a national audience on September 28, 2025, he shifted the conversation from niche medical journals to everyday discourse.

For patients, that could mean faster access to new therapies. For regulators, it could mean greater pressure to modernise outdated frameworks. And for companies producing APIs, it means the science they have been working on in relative obscurity is finally part of a bigger story.

The next decade could redefine cannabinoids. Not as cultural symbols, not as consumer supplements, but as pharmaceutical tools with the potential to reshape how we treat some of the most challenging conditions in modern medicine.

Trump’s video was not a clinical breakthrough. But it might have been the spark that pushes cannabinoids out of the shadows and into the centre of healthcare innovation.

The post Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up appeared first on Business of Cannabis.

Source link

Cannabis Stocks Soar After Trump Endorses CBD for Seniors, Mentions Medicaid

Cannabis Stocks Soar After Trump Endorses CBD for Seniors, Mentions Medicaid

Cannabis Stocks Soar After Trump Endorses CBD for Seniors, Mentions Medicaid

Markets leapt Monday after former President Donald Trump posted a video promoting the benefits of hemp-derived CBD for older Americans and called for expanded Medicare/Medicaid access to CBD. The move sent pot stocks—and broader investor expectations—into overdrive.

What the video says and why it hit

In the nearly three-minute clip, Trump said CBD is a “gamechanger” for pain and stress relief among seniors, and urged physician education and expanded government healthcare coverage. He framed the conversation around delivering real options to older voters, and invoked his 2018 Farm Bill signature as precedent. The video was produced by the pro-cannabis nonprofit Commonwealth Project and released across social media platforms.

The market reaction was immediate: cannabis ETFs, major cultivators, and consumer product companies all posted gains—reflecting how sensitive this sector is to political signaling, even absent concrete policy changes.

The investor mindset: hope vs reality

Much of today’s rally is speculative: investors are betting on possible future reforms—rescheduling, insurance expansion, or regulatory loosening. But the shift from rhetoric to regulation is rarely seamless. Without statutory changes, Trump’s statements don’t override existing law.

The surging valuations also underscore how narrow the leeway is: many cannabis companies remain unprofitable, struggling under tax burdens, compliance costs, and banking challenges. A policy nudge can spark optimism—but long-term gains depend on structural change, not just headlines.

What would actual reform look like?

  • Schedule reclassification: If marijuana moves to Schedule III, it could unlock tax deductions, insurance coverage, and broader financial legitimacy.
  • FDA & insurance framework for CBD: If federal health programs begin covering CBD, it would legitimize the market and expand demand well beyond wellness shops into medical corridors.
  • Regulatory clarity & safety rules: Deeper labeling, dosing, FDA standards, and enforcement regimes would need to accompany policy shifts to prevent miscommunication or backlash.
  • Gradual institutional entry: Even under reform, many institutional investors and banks will adopt cautious, staged approaches to cannabis exposure—especially in states with divergent regulations.

Risks beneath the surface

  • Electoral posturing: Political endorsements are often timed for impact; momentum depends on legislative backing (and party alignment).
  • DEA inertia: Trump’s DEA administrator, Terrance Cole, left cannabis rescheduling off his published priorities—suggesting agency leadership may lag behind political gestures.
  • Market fatigue: Over time, valuations built on promises can slide if real change lags. Investors may start pricing in “political risk discount” if reforms stall.
  • Divisive backlash: As approvals expand, some constituencies may push back—especially if THC gets entangled in coverage debates.

Moving from hype to policy

The cannabis sector is effectively living in the “expectation economy”—moments like Trump’s video shift sentiment, but enduring gains will depend on measurable legislative or administrative follow-through. The most durable winners won’t be juiced by the tweet — they’ll be those who align strategy with policy, compliance, and innovation.

👉 Audience Question:

Was Trump’s CBD video a turning point—or just another headline moment? What concrete reform would you demand now to translate market optimism into sustainable industry change?

The post Cannabis Stocks Soar After Trump Endorses CBD for Seniors, Mentions Medicaid appeared first on Merry Jane.

Source link

Marijuana Might Be Beneficial in Combatting Phobias

Marijuana Might Be Beneficial in Combating Phobias

Marijuana Might Be Beneficial in Combating Phobias

For some, it might mean feeling a little uneasy when matched with an unknown entity that catches them off guard when they least expect it, or a looming dread of a weekly editorial meeting that keeps them from wanting to get out of bed. Hey, we’ve been there. There are other people, however, who have an irrational, crippling fear (otherwise known as a phobia) of something that hinders their lives with such ferocity that they will do everything in their power to maintain a safe distance.

You won’t catch these folks in or even around an airport, near the snake pit at the local zoo, in confined spaces, or checking out the view from the top of the Empire State Building. Oh, hell no. People with phobias are perfectly content living their lives without any of these perceived frightening situations turning them into a frayed ball of nerves. Maybe even you have a phobia that you’ve lived with ever since you can remember that still, to this day, scares the holy bejeezus out of you. You’d do anything to avoid facing it. But don’t feel bad, you’re not alone. Around 19 million people all across the U.S. suffer from an irrational fear of something, which makes it the most common mental disorder in the country, according to the National Institute of Mental Health.

There is no need to fear, though, cannabis might be just what the doctor ordered. A body of evidence has emerged over the past six years or so suggesting that marijuana, or at least some of its essential compounds, might be able to help people with certain kinds of phobias be less afraid.

A study from the University of Michigan, which was published in the journal Neuropsychology in 2013, finds that tetrahydrocannabinol (THC) might provide phobia patients with a trapdoor out of the horrific anxiety that comes with these conditions. In some cases, researchers discovered that the stoner cannabinoid is so beneficial in this respect that it even allowed some patients to work through their fears and moved past them. But it’s not like researchers just got a bunch of people super stoned and then tossed them in a closed space and let them work out their anxieties.

The study, which involved around 30 people, used a Pavlovian fear extinction paradigm and simultaneous skin conductance response recording while dosing patients with a synthetic version of THC called dronabinol, according to Science Direct. Still, researchers say that people under the influence of THC showed less fear over time. “These results provide the first evidence that pharmacological enhancement of extinction learning is feasible in humans using cannabinoid system modulators, which may thus warrant further development and clinical testing,” the study authors wrote.

Another study, this one from the Frontiers of Pharmacology, shows that America’s favorite non-intoxicating cannabis compound cannabidiol (CBD) might actually have some therapeutic benefit when it comes to dealing with specific phobias. The study, which was led by Chenchen Song of the University of Birmingham in 2017, shows that 10 mg injections of CBD were able to reduce the fear memory in rats. Sure, it’s not likely that these animals were afraid of heights or flying, but Song says that the cannabis component did make them less fearful of being eaten alive by predators. It’s the same reason that the compound has been shown effective in treating people with post-traumatic stress disorder (PTSD). Essentially, some phobias, just like PTSD, manifest after a harrowing situation. The gist of the research is that CBD, which has gained some notoriety as an anxiety-squashing drug, was effective at preventing this fear from coming to the surface.

“In the more translationally-relevant stronger conditioning setting, CBD both acutely inhibited fear expression and enhanced extinction to produce longer-lasting reductions in fear,” the study reads. “These observations provide further support for the potential translational use of CBD in conditions such as post-traumatic stress disorder and specific phobias.”

It is possible, considering this body of evidence, that phobia patients might be able to contend with their fears with the use of medical marijuana. Traditionally, these conditions have been dealt with by prescribing beta-blockers, antidepressants and tranquilizers, but these drugs can be habit-forming and make a person feel less human than an irrational fear of anything. Still, it’s okay to be skeptical about the power of cannabis when it comes to treating phobia cases. I am. I mean, I’ve been pretty stoned in my day and never once was there a time when I felt any less freaked out by the thought of a snake slithering up next to me. And getting high and traveling to the top of the Empire State Building last year, well, that just gave me vertigo and made the experience even more frightening than it would have been under normal circumstances. However, at its most basic level, some strains of marijuana (Somari, Super Skunk Auto and Bigfoot) have been known to calm the anxiety that one experiences when those phobias kick in. Our best advice is to check with your budtender to find out what other fraidy cats are using to get through the terror.

TELL US, have you ever used cannabis to deal with a terrifying fear?

The post Marijuana Might Be Beneficial in Combating Phobias appeared first on Cannabis Now.

Source link